08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
On April 22, 2020, the UK Competition and Markets Authority published guidance on its approach to me...
Read More >
Venture capital and private equity arrangements often include contractual provisions limiting the ri...
Read More >
Welcome to our quarterly pensions litigation briefing, designed to help pensions managers identify k...
Read More >
Kilpatrick Townsend’s Larry Prosen recently joined other expert panelists at a Washington Building ...
Read More >
Employers should realize by now that misclassification of employees as independent contractors can r...
Read More >
Philadelphia and Pittsburgh issued guidance on Wednesday, April 29 for the May 1 resumption of const...
Read More >